U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07558850) titled 'Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases' on April 23.
Brief Summary: A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA-UCAR-T cells in patients with autoimmune diseases.
36-72 patients are planned to be enrolled in the dose-escalation trial.
Study Start Date: May 10
Study Type: INTERVENTIONAL
Condition:
Rheumatoid Arthritis
Dermatomyositis
Systemic Lupus Erythematosus
Systemic Sclerosis
Intervention:
BIOLOGICAL: anti-CD19/BCMA-UCAR-T cells
Patients will receive Fludarabine and Cyclo...